131 related articles for article (PubMed ID: 27338302)
1. A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy.
Li X; Xu JX
J Theor Biol; 2016 Oct; 406():42-51. PubMed ID: 27338302
[TBL] [Abstract][Full Text] [Related]
2. Modeling Pancreatic Cancer Dynamics with Immunotherapy.
Hu X; Ke G; Jang SR
Bull Math Biol; 2019 Jun; 81(6):1885-1915. PubMed ID: 30843136
[TBL] [Abstract][Full Text] [Related]
3. Whole blood interferon-γ levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer.
Ishikawa T; Kokura S; Sakamoto N; Okayama T; Endo M; Tsuchiya R; Okajima M; Matsuyama T; Adachi S; Kamada K; Katada K; Uchiyama K; Handa O; Takagi T; Yagi N; Ando T; Uno K; Naito Y; Yoshikawa T
Int J Cancer; 2013 Sep; 133(5):1119-25. PubMed ID: 23420507
[TBL] [Abstract][Full Text] [Related]
4. MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.
Wang Z; Liu Y; Zhang Y; Shang Y; Gao Q
Oncotarget; 2016 Jan; 7(4):4760-9. PubMed ID: 26716894
[TBL] [Abstract][Full Text] [Related]
5. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
8. Primary analysis for clinical efficacy of immunotherapy in patients with pancreatic cancer.
Chen L; Zhang X
Immunotherapy; 2016 Feb; 8(2):223-34. PubMed ID: 26565954
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of pancreatic cancer.
Sunami Y; Kleeff J
Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
[TBL] [Abstract][Full Text] [Related]
10. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
Khallouf H; Märten A; Serba S; Teichgräber V; Büchler MW; Jäger D; Schmidt J
J Immunother; 2012 Apr; 35(3):245-53. PubMed ID: 22421942
[TBL] [Abstract][Full Text] [Related]
11. A mathematical model for pancreatic cancer growth and treatments.
Louzoun Y; Xue C; Lesinski GB; Friedman A
J Theor Biol; 2014 Jun; 351():74-82. PubMed ID: 24594371
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.
Karakhanova S; Ryschich E; Mosl B; Harig S; Jäger D; Schmidt J; Hartwig W; Werner J; Bazhin AV
Br J Cancer; 2015 Mar; 112(6):1027-36. PubMed ID: 25742476
[TBL] [Abstract][Full Text] [Related]
13. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.
Sideras K; Braat H; Kwekkeboom J; van Eijck CH; Peppelenbosch MP; Sleijfer S; Bruno M
Cancer Treat Rev; 2014 May; 40(4):513-22. PubMed ID: 24315741
[TBL] [Abstract][Full Text] [Related]
14. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
15. Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses.
Linnebacher M; Maletzki C; Emmrich J; Kreikemeyer B
J Immunother; 2008 Oct; 31(8):704-13. PubMed ID: 18779749
[TBL] [Abstract][Full Text] [Related]
16. Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma.
Eisold S; Schmidt J; Ryschich E; Gock M; Klar E; von Knebel Doeberitz M; Linnebacher M
Pancreas; 2007 Jul; 35(1):63-72. PubMed ID: 17575547
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.
Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H
Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388
[TBL] [Abstract][Full Text] [Related]
18. Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.
Jiang N; Qiao G; Wang X; Morse MA; Gwin WR; Zhou L; Song Y; Zhao Y; Chen F; Zhou X; Huang L; Hobeika A; Yi X; Xia X; Guan Y; Song J; Ren J; Lyerly HK
Clin Cancer Res; 2017 Sep; 23(17):5066-5073. PubMed ID: 28611200
[No Abstract] [Full Text] [Related]
19. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.
Balli D; Rech AJ; Stanger BZ; Vonderheide RH
Clin Cancer Res; 2017 Jun; 23(12):3129-3138. PubMed ID: 28007776
[No Abstract] [Full Text] [Related]
20. Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer.
Kumai T; Mizukoshi E; Hashiba T; Nakagawa H; Kitahara M; Miyashita T; Mochizuki T; Goto S; Kamigaki T; Takimoto R; Yamashita T; Sakai Y; Yamashita T; Honda M; Tomita K; Kaneko S
Cytotherapy; 2021 Feb; 23(2):137-145. PubMed ID: 32907781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
